This Bill Gates-backed coronavirus vaccine developer has skyrocketed 431% in just 2 days after going public
Advertisement
Carmen Reinicke
Aug 18, 2020, 01:00 IST
FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in TuebingenReuters
Advertisement
CureVac, a German biotechnology company, skyrocketed in its initial public offering on Friday, raising $213.3 million and more than tripling from its IPO price.
Shares of the company have continued to surge since its Friday IPO, gaining as much as 52% to $85 per share on Monday — a 431% jump from the company's $16 IPO price.
The company is backed by billionaire Microsoft founder Bill Gates and is working on a potential coronavirus vaccine.
In its public trading debut, shares more than tripled, ending the day up 249% at $55.90 per share. On Monday, the biotech company's epic rally continued as shares surged as much as 52% to reach an all-time high of $85 per share.
CureVacsaid in a regulatory filing that it will use the proceeds from its IPO for research and development, expanding its manufacturing capabilities, and to fund the clinical development of its potential coronavirus vaccine through the completion of its Phase 3 trial.
The company in June started its Phase 1 coronavirus vaccine trial with healthy human participants, and expects results in the fourth quarter of the year, according to the SEC filing. In addition to the coronavirus, CureVac is working on vaccines for rabies and other infectious diseases as well as treatments for tumors, cancers, and other diseases.
"Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs," the company said in the filing.
{{}}
NewsletterSIMPLY PUT - where we join the dots to inform and inspire you. Sign up for a weekly brief collating many news items into one untangled thought delivered straight to your mailbox.
An investor whose fund returned 4,144% in the first quarter explains why tail-risk strategies are too dangerous for the average trader — and calls continued Fed stimulus 'very, very destructive'
Rackspace soars 19% after report says Amazon is eyeing a minority stake in cloud services provider
Mortgage delinquencies surge more than 8% to a 9-year high as the coronavirus pandemic hits a corner of the housing market